Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo ...

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Replicate Bioscience will partner with Novo Nordisk to develop treatments using self-replicating RNA technology for obesity, type 2 diabetes and other cardiometabolic diseases, the privately held ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Novo Nordisk agreed to collaborate with Replicate Biosciences to develop potential new treatments for obesity, type 2 diabetes and other cardiometabolic diseases, as it grapples with mounting ...

Novo Nordisk has taken the next step in selling its drugs directly to patients by pointing them to telehealth providers that ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Investing.com -- Novo Nordisk A/S has canceled contracts for new recruits just days or weeks before their start dates as part of broader cost-cutting measures, Bloomberg reports.

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...